New Therapeutics Approach in gastroenterology. Abou Rached Antoine, MD, MBAIP
|
|
- Rosalind Harrison
- 6 years ago
- Views:
Transcription
1 New Therapeutics Approach in gastroenterology Abou Rached Antoine, MD, MBAIP
2 Helicobacter pylori is a Gramnegative, microaerophilic, spiral-shaped bacterium Major cause of Chronic Gastritis PUD Colonizes Stomach 30%-80% Sero-prevalence affects CV, Respiratory, Autoimmu ne Treat in PIDA & ITP Helicobacter pylori 1994 WHO Class I carcinogen/definite MALToma, Adenocarcinoma
3 Prevalence of H. pylori infection 14-46% 81% 85% 88% 37-50% 27% 80% 43% 58% 63% 68% 90% 80% 918 million people 80% 60-70% 80% 80% 5-30% 824 million people 15-38% 36-73%
4 INDICATIONS FOR DIAGNOSING AND TREATING H. PYLORI INFECTION? Established Active peptic ulcer disease History of peptic ulcer disease (not treated) Gastric MALT lymphoma (low grade) After endoscopic resection of early gastric cancer Uninvestigated dyspepsia Controversial Nonulcer dyspepsia GERD Persons using NSAID Unexplained iron deficiency anemia Populations at higher risk for gastric cancer
5 Diagnosis of H. Pylori I. Diagnostic non-invasive tests II. Diagnostic invasive tests
6 Diagnostic Testing for H. pylori: noninvasive tests Non-endoscopic Testing Advantages Disadvantages Antibody testing Inexpensive, widely available, very good NPV/PPV dependent upon H. pylori prevalence. Not recommended after H. pylori therapy Urea breath tests Identifies active H. pylori infection. Excellent PPV and NPV Useful before and after therapy Reimbursement and availability remain inconsistent Fecal antigen test Identifies active H. pylori infection. Excellent PPV & NPV regardless of H. pylori prevalence. Useful before and after H pylori therapy Polyclonal test less validated than UBT in post-treatment. Monoclonal test reliable before and after antibiotic therapy.
7 Endoscopy-Based Testing for H. pylori Endoscopic testing Advantage Disadvantage Histology Excellent sensitivity and specificity Expensive and requires infrastructure and trained personnel Rapid urease testing Inexpensive and provides rapid results. Excellent specificity and very good sensitivity in properly selected patients Sensitivity significantly reduced in the Post-treatment setting Culture Excellent specificity. Allows determination of antibiotic sensitivities Expensive, difficult to perform, and not widely available. Only marginal sensitivity PCR Excellent sensitivity and specificity. Allows determination of antibiotic sensitivities Methodology not standardized across laboratories and not widely available
8 Diagnostic Testing for H. pylori: Advantages of Serology Not affected by local changes in the stomach The bacterial load can be decreased under the threshold of detection with the other methods: transitorily, in case of antimicrobial or antisecretory drugs consumption permanently in case of premalignant & malignant lesions Antibodies (CagA antibodies) remain elevated for months-years after H. pylori disappearance in the stomach
9 Treatment Regimens Triple therapy Quadruple therapy Sequential Classic therapy (7-14d): Amoxicillin, Clarithromyci n, PPI Clarithromycin, metronid azole, PPI Amoxicillin, levofloxacin, PPI Bismuth Based: Tetracycline, bismuth, m etronidazole, PPI (10 days) Non-bismuth based: Clarithromycin, metroni dazole, amoxicillin, PPI (10days) 5 days: PPI + Clarithromycin 5 days: amoxicillin, metronidaz ole +PPI
10 Primary resistance to clarithromycin (%) Failure rate of triple therapy: 69.5% if clarithromycin resistance 25% if metronidazol e resistance Eradication rate after triple therapy (%) *Fischbach L, et al. Aliment Pharmacol Ther 2007; 26(3): ; **. Mégraud F. Gut 2004; 53(9): ; ***. Sasaki M, et al. J Clin Biochem Nutr 2010; 47(1):53-8.
11 Rate of Primary Clarithromycin Resistance in H. Pylori in Europe ( )
12 Maastricht IV: Treatment recommendation
13 How to improve the standard triple therapy? Use high dose PPI: twice daily Increase the duration of the therapy from 7 to days will increase the eradication rate by 5% PPI-clarithromycin-metronidazole (PCM) and PPIclarithromycin-amoxicillin (PCA) regimens are equivalent. Certain probiotics and prebiotics show promising results as an adjuvant therapy in reducing side effects. PPI-clarithromycin containing therapies do not need to be adapted to patient factors except for dosing
14 Second line therapy After failure of PPI Clarithromycin containing therapy either: Bismuth based quadruple therapy OR Levofloxacin based triple therapy (take into account rising resistance to fluoroquinolone) After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing whenever possible.
15 High Clarithromycin-Resistant area In areas of high clarithromycin resistance, bismuth-containing quadruple therapies are recommended for first-line empirical treatment. If this regimen is not available sequential therapy or a non-bismuth quadruple therapy is recommended. Evidence Level: 1a Grade of Recommendation: A
16 Second and Third Line In areas of high clarithromycin resistance after failure of bismuth-containing quadruple therapy: Levofloxacin containing triple therapy is recommended. Rising rates of levofloxacin resistance should be taken into account After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing whenever possible.
17 Treatment Algorithm: Maastricht IV 1 st line 2 nd line 3 rd line
18 ACG ACG Treatment Algorithm Recommendation
19 Hepatitis B
20 The global impact of HBV disease 2 billion with evidence of HBV infection 25 40% die of cirrhosis or liver cancer World population ~6 billion million with chronic hepatitis B WHO, Fact sheet No. 204; CDC, Viral hepatitis B fact sheet; Conjeevaram HS, Lok AS. J Hepatol. 2003;38:S Lee WM. N Engl J Med. 1997;337: Lok AS. N Engl J Med. 2002;346:1682-3
21 Epidemiology Worldwide Prevalence of Hepatitis B World prevalence of HBV carriers HBsAg carriers prevalence <2% 2-7% 8% poorly documented WHO 2003.
22 Transmission of HBV Vertical (perinatal) transmission Horizontal transmission 90% of infected infants become chronically infected Mother Host 6% of people infected over the age of 5 become chronically infected Infant Recipient Child-to-child Contaminated needles Sexual contacts Healthcare worker Blood transfusion CDC Viral hepatitis B fact sheet; Lee. N Engl J Med. 1997;337: ; Lavanchy. J Viral Hepat. 2004;11:97-107
23 Epidemiology of hepatitis B and C in general population in Lebanon Prospective study: January 2010 December 2011 Screening of the general population in different regions for hepatitis B and hepatitis C
24 Epidemiology of hepatitis B and C in Results: general population in Lebanon Over 2 year period: 31,137 individuals screened ( 0.7% of population) Sex: 51% male 49% female Mean age: Male: 37.1 (range 5-89) Female: 38.4 (range 8-85)
25 Epidemiology of hepatitis B in general population in Lebanon Results: Prevalence of hepatitis B: 1.69% (542 patients HBsAg positive) Sex Ratio: M/F: 1.38 Male: 58% Female: 42% District distribution: Beirut: 0.73% Mount Lebanon: 1.79% South: 1.9% Bekaa Valley (East): 1.23% North: 1.7%
26 Indications for Treatment of HBV Infection Upon Diagnosis Phase of Chronic HBV Infection HBeAg Status HBV DNA Elevated? ALT Level Elevated? Treatment Indicated? Immune tolerant Positive Yes No No Immune active/clearance Positive/negative Yes Yes Yes Inactive carrier No No No No Reactivation Yes Yes Yes Yes
27 AASLD and EASL Recommendations for the Management of Chronic HBV Infection HBeAg-Positive Patients AASLD HBV DNA >20,000 IU/mL and ALT >2 x ULN a : consider treatment after 3 to 6 months of observation with absence of spontaneous loss of HBeAg HBV DNA >20,000 IU/mL and ALT 2 x ULN, and age >40 years or family history of HCC: consider liver biopsy and treat if significant histologic disease is present EASL HBV >2000 IU/mL and/or ALT >ULN: consider liver biopsy (or noninvasive markers) and treat if moderate to severe histologic disease is present HBeAg-Negative Patients AASLD HBV DNA >2000 IU/mL and ALT >2 x ULN: consider treatment HBV DNA >2000 IU/mL and ALT >ULN: consider liver biopsy and treat if significant histologic disease is present EASL HBV >2000 IU/mL and/or ALT >ULN: Consider liver biopsy (or noninvasive markers) and treat if moderate to severe histologic disease is present Cirrhotic Patients AASLD Compensated cirrhosis HBV DNA >2000 IU/mL: treat HBV DNA <2000 IU/mL and ALT >ULN: consider treatment Decompensated cirrhosis Treat with any detectable HBV DNA level EASL Compensated cirrhosis and decompensated cirrhosis Treat regardless of the HBV DNA level
28 Antiviral Agents Approved for the Treatment of Chronic HBV Infection Oral Antiviral Agents Drug Dose a Lamivudine: pill or oral solution Entecavir: pill or oral solution Telbivudine: pill Adefovir dipivoxil: pill Tenofovir disoproxil fumarate: pill or oral solution 100 mg, once daily 0.5 mg, once daily 600 mg, once daily 10 mg, once daily 300 mg, once daily Injection Immunostimulators Drug Dose Interferon alfa-2b Pegylated interferon alfa-2a 10 million units by SC injection 3 times/wk for wk 180 μg by SC injection weekly for 48 wk
29 Cumulative Annual Incidence of Resistance of Nucleos(t)ide Analogs
30 Antiviral resistance increases over time Lamivudine 1 Telbivudine 4 40 Incidence of resistance (%) 5% Adefovir 2 Entecavir (LAM-resistant) 3 Entecavir (naive) 3 *** 12% 24% 15% 20% 11% 0.1% 0% 0.3% 2% 0.4% 0.8% Year 1 Year 2 Year 3 Resistance to NAs is it just a matter of time?? 42% 25% 53% 40% 18% Year 4 70% 29% 65% Year 5 1 Lai, Clin Infect Dis 2003; 2 Westland, Hepatology 2003; 3 Colonno R, EASL 2007; 4 Gane, EASL 2006 Slide 25
31 Hepatitis C
32
33 Epidemiology of Hepatitis C in General Population in Lebanon Results: Prevalence of hepatitis C: 0.2% (HCV Ab positive) Sex Ratio: M/F: 0.85 PCR HCV: Male: 46% Female: 54% Positive: 84.6% Negative: 15.4%
34 Hépatite virale C
35 virale hepatitis C Futur of the concept new molecules Triple therapy Pegylated Interferon + Ribavirine + telaprevir Pegylated Interferon + Ribavirine + Boceprevir Vaccin against hépatitis C
36
37 Response-guided therapy algorithm for boceprevir
38
39
40 Response-guided therapy algorithm for telaprevir.
41
42
43
44 Classes of drugs in development for hepatitis C Drug class Mechanism of action Advantages Disadvantages NS3/4A protease inhibitors First generation NS3/4A protease involved in posttranslation processing of HCV polyproteins Potent inhibitors of HCV genotype 1 Low genetic barrier to resistance Cross-resistance is extensive between different compounds in class Drug interactions (CYP) Second generation NS3/4A protease involved in posttranslation processing of HCV polyproteins Pan-genotypic antiviral activity Higher genetic barrier to resistance than first-generation PIs; activity against many substitutions that cause resistance in first-generation PIs NS5B polymerase inhibitors NS5B RdRp is required for copying HCV-RNA genome and transcribing mrna Nucleoside inhibitors Analogs of natural substances; bind active site of RdRp; terminate viral RNA chain generation High barrier for resistance Pan-genotypic Fewer in pipeline Non-nucleoside inhibitors Bind various allosteric sites, inducing conformational change in polymerase Multiple target sites identified Low/medium antiviral efficacy Active against genotype 1 Low genetic barrier HCV genotype-/subtypedependent NS5A inhibitors Bind domain I of NS5A protein, exact role in viral replication is unclear High potency Potential activity against multiple genotypes Low genetic barrier to resistance Cyclophilin Inhibitors Target host cyclophilin enzyme; functional regulator of HCV replication Good potency Pan-genotypic High barrier to resistance Drug interactions
45 Hepatitis C virus direct-acting antiviral therapy agents in clinical development in phases II/III clinical trials NS3/NS4A protease inhibitors Phase 2 Phase 3 Licensed First generation Danoprevir/r* (RG7227) Sovaprevir (ACH-1625) GS-9256 GS-9451 ABT-450/r* Vaniprevir (MK7009) Simeprevir (TMC435) Faldaprevir (BI201335) Asunaprevir (BMS ) Boceprevir Telaprevir Second generation MK-5172 NS5B polymerase inhibitors Nucleos(t)ide analogs Mericitabine (RG7128); IDX-184 PSI-7851 Sofosbuvir (GS-7977) Non-nucleos(t)ide analogs VX-222 BMS ABT-333 ABT-072 Setrobuvir(ANA598) BI Filibuvir IDX375 VCH-916 [tegobuvir (GS-9190)] NS5A inhibitors ABT-267 GSK GS-5885 Daclatasvir (BMS ) Cyclophilin NIM-811; SCY-635 [Alisporivir]
46 Future There are many potential therapeutic options for treatment It is not yet clear whether there will be a single major treatment option used for all genotypes of HCV or whether there will be an individualized therapeutic approach that considers viral genotype, IL28B genotype, resistance mutations other factors in planning a treatment for each patient. there may be a truly realizable goal of providing curative management for the majority of patients with HCV who are treated
Treatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHCV eradication with direct acting antivirals (DAAs)?
HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr HCV eradication with direct
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationCase #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals
Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University School of Medicine
More informationThe Egyptian Plan to Cure HCV
The Egyptian Plan to Cure HCV Gamal Esmat Professor of Endemic Medicine & Hepatology Vice President of Cairo University for Graduate Studies and Research Disclosure Advisory Committee Board Member : MSD,
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationHBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD
HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationResistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology
More informationPharmacologic Considerations when using DAAs in Cirrhosis
Pharmacologic Considerations when using DAAs in Cirrhosis Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Denver 1 st International Workshop on the Optimal Use of DAAs in Liver Transplant
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationMANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman
MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHepatitis C in HIV-infected Persons. Andrea Cox, MDPhD, Ashwin Balagopal, MD
Hepatitis C in HIV-infected Persons Andrea Cox, MDPhD, Ashwin Balagopal, MD Case 1 45 year old Caucasian man with HIV, CD4+ lymphocyte 756/mm 3 HIV RNA undetectable presents for routine follow up with
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationNorth Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low
The prevalence of CHB varies widely across EMEA (Europe, Middle East & North Africa) 8% High 2 8% Intermediate
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHelicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師
Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationViral Hepatitis Update. Andrew Scanga, M.D. Assistant Professor of Medicine September 12 th 2015
Viral Hepatitis Update Andrew Scanga, M.D. Assistant Professor of Medicine September 12 th 2015 Outline Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Hepatitis A Identified in 1973 RNA virus
More informationMinimum costs to produce Hepatitis C Direct Acting Antivirals
Minimum costs to produce Hepatitis C Direct Acting Antivirals Andrew Hill and Saye Khoo, Department of Pharmacology and Therapeutics, Liverpool University, UK Bryony Simmons, Imperial College, London,
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationNew Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain
New Treatments for Chronic Hepatitis C Rafael Esteban Hospital Valle Hebron. Barcelona Spain The present: a complex treatment with a better SVR Genotype 1 Genotypes 2 and 3 Triple therapy Boceprevir (BOC)
More information